Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 2.17 +0.12 (+5.85%)
As of 05/15/2026 12:39 PM Eastern
Compare

GENF vs. HEMO, COIL, POLB, COS, and C4XD

Should you buy Genflow Biosciences stock or one of its competitors? MarketBeat compares Genflow Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genflow Biosciences include Hemogenyx Pharmaceuticals (HEMO), Roquefort Therapeutics (COIL), Poolbeg Pharma (POLB), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Genflow Biosciences has a net margin of 840.76% compared to Hemogenyx Pharmaceuticals' net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Genflow Biosciences 840.76%377.33%-58.66%

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Genflow Biosciences Neutral

0.2% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Comparatively, 47.5% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Hemogenyx Pharmaceuticals has a beta of 1.544, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.108, indicating that its stock price is 111% more volatile than the broader market.

Summary

Genflow Biosciences beats Hemogenyx Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Genflow Biosciences (LON:GENF) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 1.2% of Roquefort Therapeutics shares are owned by institutional investors. 47.5% of Genflow Biosciences shares are owned by company insiders. Comparatively, 22.6% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Roquefort Therapeutics Neutral

Genflow Biosciences has a net margin of 840.76% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 377.33% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Roquefort Therapeutics -57,057.07%-18.30%-15.86%

Genflow Biosciences has a beta of 2.108, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, suggesting that its stock price is 95% less volatile than the broader market.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£6.30N/A

Summary

Genflow Biosciences beats Roquefort Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to Poolbeg Pharma?

Genflow Biosciences (LON:GENF) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are owned by institutional investors. 47.5% of Genflow Biosciences shares are owned by insiders. Comparatively, 7.6% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Poolbeg Pharma had 6 more articles in the media than Genflow Biosciences. MarketBeat recorded 6 mentions for Poolbeg Pharma and 0 mentions for Genflow Biosciences. Genflow Biosciences' average media sentiment score of 0.00 beat Poolbeg Pharma's score of -0.18 indicating that Genflow Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Genflow Biosciences Neutral
Poolbeg Pharma Neutral

Genflow Biosciences has a net margin of 840.76% compared to Poolbeg Pharma's net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Poolbeg Pharma N/A -55.47%-21.33%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Genflow Biosciences has a beta of 2.108, indicating that its stock price is 111% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.819, indicating that its stock price is 82% more volatile than the broader market.

Summary

Genflow Biosciences beats Poolbeg Pharma on 7 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to Collagen Solutions plc (COS.L)?

Collagen Solutions plc (COS.L) (LON:COS) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Collagen Solutions plc (COS.L)'s average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Collagen Solutions plc (COS.L) Neutral
Genflow Biosciences Neutral

Collagen Solutions plc (COS.L) has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than Collagen Solutions plc (COS.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collagen Solutions plc (COS.L)£4.01M0.00N/A-£0.80N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Genflow Biosciences has a net margin of 840.76% compared to Collagen Solutions plc (COS.L)'s net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Collagen Solutions plc (COS.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Collagen Solutions plc (COS.L)N/A N/A N/A
Genflow Biosciences 840.76%377.33%-58.66%

0.1% of Genflow Biosciences shares are owned by institutional investors. 47.5% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Genflow Biosciences beats Collagen Solutions plc (COS.L) on 6 of the 8 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

Genflow Biosciences (LON:GENF) and C4X Discovery (LON:C4XD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
C4X Discovery£24.68M0.00£10.57M£0.04N/A

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled C4X Discovery'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
C4X Discovery Neutral

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 52.1% of C4X Discovery shares are held by institutional investors. 47.5% of Genflow Biosciences shares are held by insiders. Comparatively, 27.1% of C4X Discovery shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genflow Biosciences has a net margin of 840.76% compared to C4X Discovery's net margin of 42.81%. Genflow Biosciences' return on equity of 377.33% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
C4X Discovery 42.81%55.38%28.04%

Genflow Biosciences has a beta of 2.108, meaning that its stock price is 111% more volatile than the broader market. Comparatively, C4X Discovery has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Summary

C4X Discovery beats Genflow Biosciences on 6 of the 10 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£12.18M£473.10M£6.38B£2.71B
Dividend YieldN/A3.86%2.81%6.15%
P/E Ratio-6.543.8320.66365.91
Price / SalesN/A7,766.09552.7988,030.07
Price / Cash3.0013.1342.4327.89
Price / Book8.7484.219.877.74
Net Income-£1.76M-£96.07M£3.57B£5.89B
7 Day Performance-7.66%0.91%0.23%0.21%
1 Month Performance-1.36%-0.01%-2.54%0.63%
1 Year Performance126.04%68.91%33.54%78.11%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 2.17
+5.9%		N/A+126.0%£12.18MN/AN/A5
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 629
-5.1%		N/A+278.6%£40.41MN/AN/A14
COIL
Roquefort Therapeutics
N/AGBX 8
flat		N/A-46.6%£34.07MN/AN/A9
POLB
Poolbeg Pharma
N/AGBX 4.70
+4.4%		N/A+69.3%£33.14MN/AN/A12
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01MN/A3,350

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 5/17/2026 by MarketBeat.com Staff.
From Our Partners
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel
Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the bigg...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel